\
&
Contact us
\
&
Contact us
Published on | 2 weeks ago
ProgrammesEIT Health (European Institute of Innovation and Technology) invites applications for funding innovative digital and AI-powered medical technologies.
In order for the project to be eligible, the consortium involved must be composed of at least two organisations from different countries, including a commercialising company. Proposed solutions must be digital or AI-enabled medical devices at Innovation Maturity Level 6 (IML), with the aim of reaching IML 7 by the project's conclusion.
EIT Health will provide funding of up to 50% of the total project budget, capped at €850,000 per project. The funding period can last up to 24 months, encompassing pivotal clinical studies, regulatory submissions, product finalisation, and market strategies.
This call closes on 6 May 2026. Interested participants can join an information session on 18 March at 12h and engage in an Open Q&A Session on 8 April and 22 April.
For more details on eligibility and the application process, interested parties can refer to the website of the call.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The European Commission has published a new round of calls under the Digital Europe programme. The submission period for the following call topics will open on 21 April 2026: Apply AI: Piloting AI-based image screening in medical centres Digital solutions for regulatory compliance through data Advanced Digital Skills for AI Uptake in Health... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
